Trevi Therapeutics Business Summary

Trevi Therapeutics, Inc. (TRVI) is a clinical-stage biopharmaceutical company that currently operates as a pre-revenue entity, with a business model centered on the development and eventual commercialization or strategic licensing of its lead investigational therapy, Haduvio (oral nalbuphine ER). The company’s primary business segments are dedicated to addressing unmet medical needs in chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Trevi distinguishes itself by utilizing a dual-acting opioid receptor ligand to target the neural pathways of cough, aiming for a differentiated efficacy and safety profile in specialty respiratory markets. Direct competitors include GSK (developing camlipixant), Merck (gefapixant), and Nocion Therapeutics; Trevi positions itself as a late-stage clinical contender focusing on niche, high-morbidity indications where it seeks to outperform systemic P2X3 receptor antagonists through its unique mechanism of action. The company was co-founded by President and CEO Jennifer Good and Chief Scientific Officer Thomas Sciascia, M.D., both of whom previously held senior leadership roles at Penwest Pharmaceuticals prior to its acquisition. The executive suite was further strengthened in January 2026 by the appointment of Chief Financial Officer David Hastings, a veteran with over 25 years of experience at Incyte and Arbutus Biopharma, alongside Chief Development Officer James Cassella, Ph.D., who brings extensive CNS drug development expertise. Trevi maintains strong institutional backing from notable investors such as New Enterprise Associates (NEA), Frazier Life Sciences, and Viking Global Investors. The board of directors is chaired by David Meeker, M.D., the former CEO of Genzyme, providing significant clinical and commercial pedigree as the company prepares for pivotal Phase 3 development.